Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands ...

Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter 2025 Earnings Conference Call. At this time, all participants are in a ...

In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Keytruda works by inhibiting the PD-1 receptor, disrupting cancer's ability to escape immune surveillance. It has received approvals for multiple cancer types, demonstrating significant clinical ...

Keytruda works by inhibiting the PD-1 receptor, disrupting cancer's ability to escape immune surveillance. It has received approvals for multiple cancer types, demonstrating significant clinical ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

Molecular characterization of an extensive lung cancer patient-derived xenograft (PDX) resource.